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Abstract: Colorectal cancer (CRC) is one of the most malignant and fatal cancers worldwide.
Although cytoreductive surgery combined with chemotherapy is considered a promising therapy,
peritoneal adhesion causes further complications after surgery. In this study, oxaliplatin-loaded
Poly-(d,l-lactide-co-glycolide) (PLGA) microparticles were prepared using a double emulsion method
and loaded into hyaluronic acid (HA)- and carboxymethyl cellulose sodium (CMCNa)-based
cross-linked (HC) hydrogels. From characterization and evaluation study PLGA microparticles
showed smaller particle size with higher entrapment efficiency, approximately 1100.4 ± 257.7 nm and
77.9 ± 2.8%, respectively. In addition, microparticle-loaded hydrogels showed more sustained drug
release compared to the unloaded microparticles. Moreover, in an in vivo pharmacokinetic study after
intraperitoneal administration in rats, a significant improvement in the bioavailability and the mean
residence time of the microparticle-loaded hydrogels was observed. In HC21 hydrogels, AUC0–48h,
Cmax, and Tmax were 16012.12 ± 188.75 ng·h/mL, 528.75 ± 144.50 ng/mL, and 1.5 h, respectively.
Furthermore, experimental observation revealed that the hydrogel samples effectively protected
injured tissues from peritoneal adhesion. Therefore, the results of the current pharmacokinetic study
together with our previous report of the in vivo anti-adhesion efficacy of HC hydrogels demonstrated
that the PLGA microparticle-loaded hydrogels offer novel therapeutic strategy for CRC treatment.
Keywords: oxaliplatin; PLGA; hydrogel; intra-abdominal anti-adhesion barrier; colorectal cancer
1. Introduction
Colorectal cancer (CRC) is one of the most malignant cancers worldwide. Although the incidence
of CRC is low, the number of new cases that are malignant and fatal is still the highest among both
men and women. In addition, peritoneal carcinomatosis is one of the numerous manifestations of
CRC identified at the first diagnosis in more than 10% of CRC patients, and it is extremely fatal,
with median survival of approximately 6 months [1,2]. The treatment strategies for both CRC and
peritoneal carcinomatosis patients depend on the type and stage, and optimal therapy comprises
cytoreductive surgery combined with chemotherapy [3].
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Peritoneal adhesion is one of the most common postoperative complications associated with
cytoreductive surgery. Previous studies indicated their occurrence in more than 50% cases, and they have
even higher recurrence rates (85–93%) [4,5]. As cytoreductive surgery and intraperitoneal chemotherapy
are closely related to the completeness of cytoreduction, problems associated with cytoreductive surgery
are still a big challenge in medical science. Therefore, hydrogel-based anti-adhesion barriers came into
the spotlight to reduce adhesion by mechanical separation of injured tissue surfaces during peritoneal
repair after surgery [6].
Oxaliplatin (Figure 1) is a third-generation, platinum-based, systemic chemotherapeutic agent for
CRC [7], and it is expected to be similarly effective in peritoneal carcinomatosis. Therefore, it is currently
being used as a part of the standard chemotherapy regimen, FOLFOX (oxaliplatin with 5-fluorouracil
and leucovorin) [8], for the clinical treatment of metastatic CRC [9]. However, a recent study conducted
in a murine model confirmed that intraperitoneally administered oxaliplatin enhanced peritoneal
tissue concentration while reducing its systemic absorption, suggesting a possible decrease in toxicity
associated with systemic chemotherapy [10]. Therefore, the new approach comprising cytoreductive
surgery followed by intraperitoneal oxaliplatin delivery has resulted in significant improvement in the
disease states of CRC and peritoneal carcinomatosis [11].
Biodegradable microparticles have been widely investigated for the controlled delivery of
chemotherapeutic agents [12,13]. In addition, neither an initial burst release, nor the presence of
a lag phase are desirable for the chemotherapeutic agents as it can be associated with adverse effects.
Poly-(d,l-lactide-co-glycolide) (PLGA) is an unique copolymer approved by the regulatory agencies for
the manufacturing of bioresorbable surgical sutures. Owing to its biodegradability and biocompatibility,
PLGA become the first line materials for the production of injectable microparticle based controlled
release system [14]. A recent report of metformin/irinotecan-loaded nanoparticles have shown an initial
2 h burst release, however, increase the drug retention time in tumor and increase drug circulation [15].
Moreover, alternative reports of paclitaxel-loaded PLGA microparticles have been evaluated for cancer
therapy. These models revealed protection of the therapeutic payload from premature burst release,
and enable the sustained release of paclitaxel [16,17].Pharmaceutics 2019, 11, x 3 of 13 
 
 
Figure 1. Chemical structures of Poly-(D,L-lactide-co-glycolide) (PLGA) microparticles and hyaluronic 
acid (HA) and carboxymethyl cellulose sodium (CMCNa)-based cross-linked (HC) hydrogel 
components (A) HA; (B) CMCNa; (C) HC hydrogel; (D) Oxaliplatin; and (E) PLGA. 
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Figure 1. Chemical structures of Poly-(d,l-lactide-co-glycolide) (PLGA) microparticles and hyaluronic
acid (HA) and carboxymethyl cellulose sodium (CMCNa)-based cross-linked (HC) hydrogel components
(A) HA; (B) CMCNa; (C) HC hydrogel; (D) Oxaliplatin; and (E) PLGA.
Recently we succeeded in synthesizing novel hyaluronic acid (HA) and carboxymethyl cellulose
sodium (CMCNa)-based cross-linked (HC) hydrogels loaded with oxaliplatin [18]. These novel HC
hydrogels significantly prevented intraperitoneal adhesion and offered the highest anti-adhesion barrier
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in an in vivo rat model. However, pharmacokinetic evaluation of oxaliplatin-loaded HC hydrogels
was not carried out. Several reports of microparticles-loaded hydrogels in various drug delivery
system showed controlled drug release for over a prolonged period [19,20]. Therefore, to provide
an adequate anti-adhesion barrier effect after cytoreductive surgery and deliver intraperitoneal
chemotherapy, oxaliplatin-loaded PLGA microparticles were prepared, characterized, and loaded
into HC hydrogels. In addition, an in vitro oxaliplatin release study of PLGA microparticle-loaded
HC hydrogels in comparison with that of commercially available Guardix-Sol® hydrogel was carried
out. Furthermore, in vivo pharmacokinetic analysis was carried out to demonstrate the efficacy of
intraperitoneal chemotherapy with oxaliplatin-PLGA microparticles loaded into HC hydrogels.
2. Materials and Methods
2.1. Materials and Animals
Oxaliplatin was a gift from Boryung Pharm (Ansan, Korea). Resomer® RG 502 H (Poly-(d,l-lactide-
co-glycolide)) PLGA, molecular weight (MW) approximately 7000–17,000, was purchased from Evonic
Ind., (Darmstadt, Germany). Hyaluronic acid (HA, MW 1000 kDa) was a gift from Huons (Seongnam,
Korea). Poly-(vinyl alcohol) (PVA, MW approximately 89,000–98,000), carboxymethyl cellulose sodium
(CMCNa, MW approximately 700 kDa), and adipic acid dihydrazide (ADH) were obtained from Sigma
Aldrich (St. Louis, MO, USA). 1-Ethyl-3-(3-(dimethylaminopropyl) carbodiimide (EDC) was purchased
from Tokyo Chemical (Tokyo, Japan). All other chemicals were of reagent grade, and Milli-Q® water
(Millipore1, Molsheim, France) was used throughout the study.
Male Sprague-Dawley (SD) rats were purchased from YoungBio (Seongnam, Republic of Korea).
The animals were housed in a semi-specific pathogen free facility using standard cages at 19 ± 1 ◦C and
50 ± 5% relative humidity, with a 12-h light-dark cycle. The rats were fed a standard diet, provided
with purified water, and allowed to move freely. All experiments were approved by the Institutional
Animal Care and Use Committee (IACUC-201809-788-01) at Yonsei University, Seoul, Korea, and were
performed according to IACUC guidelines.
2.2. Preparation of Oxaliplatin-PLGA Microparticles
Oxaliplatin-PLGA microparticles were prepared using a double emulsion method [21]. Briefly,
oxaliplatin (20 mg) was dissolved in 5 mL of deionized water (first aqueous solution, W1) containing
0.5% (w/v) PVA. The resulting oxaliplatin containing W1 was added dropwise to 12.5 mL DCM,
containing 1 g of PLGA 502 H, using a homogenizer ULTRA-TURRAX® (IKA-WERKE GMBH &
Co. KG, Staufen, Germany) at 12,000 rpm for 2 min. This primary emulsion (W1/O) was slowly
added to 100 mL of 1% (w/v) PVA solution (second aqueous solution, W2) and emulsified at 400 rpm
using magnetic stirrer for 3 h while the DCM was allowed to evaporate completely under vacuum.
The resultant microparticles were collected, washed using distilled water, centrifuged, and freeze-dried
using an ilShinBioBase (Seoul, Korea) freeze-drier under vacuum (5 mTorr). Samples were pre-frozen
for 2 h at −60 ± 1.0 ◦C prior to final drying at −88 ± 1.0 ◦C for 2 days. The collected freeze-dried
microparticles were stored at 4 ◦C and further evaluated by scanning electronic microscopy (SEM) to
characterize the morphological features.
2.3. Synthesis of HA-CMCNa Cross-Linked Hydrogels
Hydrogels were synthesized using variable ratios of HA and CMCNa (Figure 1) by chemical
cross-linking, as described by our previous study [18]. Briefly, HA and CMCNa at ratios of 1:2 and
2:1 (w/w) were dissolved in deionized water with continuous stirring. After complete dissolution,
2 mM/L of ADH was added to the mixture, and the pH was adjusted to 4.75 ± 0.05 using 0.1 M
HCl. After vortex mixing for 1 min, 2 mM/L EDC was added, and the resulting mixture was stirred
thoroughly at room temperature (25 ± 1.0 ◦C) for at least 12 h to allow for complete cross-linking.
The reaction was maintained at pH 4.75 ± 0.05 by the addition of 0.1 M HCl. Finally, the cross-linking
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reaction was terminated by elevating the pH of the mixture to 7.0 ± 0.05 via the slow addition of
0.1 M NaOH. The hydrogel samples were purified as previously described by Luo et al. [22]. Briefly,
the hydrogel samples were dispensed into a dialysis bag (Mw cut-off 18,000 Da) previously treated
with a 70% ethanol (EtOH) solution and dried. The bag was submerged and dialyzed for 12 h in 0.1 M
NaCl followed by alternating solutions of 25% EtOH for 6 h and DW for 6 h. The remaining hydrogels
in the dialysis bag were rinsed using EtOH, and then centrifuged at 2000 rpm for 10 min to remove the
remaining ADH. Finally, the precipitated hydrogels (HC12 and HC21) were collected and stored until
further experiments.
2.4. Preparation of Oxaliplatin-PLGA Microparticle-Loaded Hydrogel
Guardix-Sol® is a commercial anti-adhesive hydrogel used for the prevention of post-operative
adhesion. Above, we synthesized HC12 and HC21 hydrogel composites with variable weight ratios
of HA and CMCNa. Next, oxaliplatin-PLGA microparticles were dispersed gently in the hydrogel
(HC12, HC21, and Guardix-Sol®). Briefly, precisely weighed oxaliplatin-PLGA microparticles were
mixed with 10 mL of hydrogels at room temperature (25 ± 1.0 ◦C) with continuous stirring for 30 min.
The final concentration of oxaliplatin was 2 mg/ mL of hydrogel. After complete dissolution was
visually observed, samples were evaluated for in vitro and in vivo release of oxaliplatin.
2.5. Characterization of Oxaliplatin-PLGA Microparticles
2.5.1. Morphology
The morphology of oxaliplatin-PLGA microparticles was evaluated using SEM (JSM-6700F, JEOL,
Tokyo, Japan). Briefly, a small amount of powder was sprinkled onto double-sided adhesive tape
attached to an aluminum stub and was sputter-coated with gold under vacuum. Photographs were
taken at 5×magnification with an accelerating voltage of 1–5 kV to reveal the surface characteristics of
the particles.
2.5.2. Particle Size Analysis
The mean particle size and distribution of oxaliplatin-PLGA microparticles were analyzed by
dynamic light scattering (DLS) using an electrophoretic light scattering spectrophotometer (ELS-Z,
Otsuka Electronics, Hirakata, Japan).
2.5.3. Rheological Measurements
The rheological measurements for HC12, HC21, and Guardix-Sol® hydrogels were performed
using a Brookfield rheometer (Brookfield Digital Rheometer Model DV-III, DV3T™ Rheometer,
Middleboro, MA, USA) equipped with a Peltier system for temperature control. Precisely, about 0.5 g
of sample was applied to the plate and allowed to equilibrate. Measurements were performed at
37 ± 0.5 ◦C with shear rates ranging from 200–500 s−1. Before each measurement, the samples were
allowed to rest for 5 min at 37 ± 0.5 ◦C. Results were analyzed with Brookfield software (Firmware
version 1.2.2-9).
2.5.4. Encapsulation Efficiency
Freeze-dried oxaliplatin-PLGA microparticles (eq. 2 mg of oxaliplatin) were dissolved in 5 mL of
DCM. After 5 min of vortexing, particles were allowed to dissolve properly, and the tube was gently
swung in incubator at 37 ± 0.5 ◦C for 1 h. Then, 5 mL of DW was added to the tube and vortexed
vigorously for 1 h. The suspension was centrifuged at 12,000 rpm for 5 min to precipitate PLGA.
The upper aqueous phase was collected, and the concentration of oxaliplatin was determined by HPLC.
Encapsulation efficiency (EE %) was calculated using the following Equation (1):
EE % = Mactual oxaliplatin/Mtheoretical oxaliplatin × 100 (1)
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2.6. In Vitro Oxaliplatin Release from PLGA Microparticles Loaded into Hydrogels
To evaluate the in vitro oxaliplatin release rate from oxaliplatin-PLGA microparticles, an amount
equivalent to 2 mg of oxaliplatin was weighed and suspended in 1 mL of HPLC grade water.
The suspension was transferred into dialysis bags (MWCO 14,000) and then submerged in 20 mL
of double distilled water in capped 50 mL Falcon® tube. Samples were shaken at 30 rpm at the
predetermined time points (1, 2, 3, 4, 6, 8, and 12 h); 1 mL of sample was collected from the medium
and 1 mL of pre-warmed medium was immediately added to the tubes. Experiments were performed
in triplicate (n = 3), and the collected samples were analyzed with HPLC after necessary dilution.
The release profile was expressed as the ratio of cumulative oxaliplatin release to initial oxaliplatin
loading versus time, using the following Equation (2):
Percent of oxaliplatin release = Mt/M0 × 100 (2)
For the in vitro oxaliplatin release from the PLGA microparticle-loaded hydrogels (from
Section 2.4.), a similar method was used. Briefly, 1 mL PLGA microparticle-loaded hydrogel (HC12,
HC21, or Guardix-Sol®) was transferred to one end-closed dialysis bags (MWCO 14,000). The other
end of the bag was closed properly, and the samples were submerged in 20 mL of double distilled
water in capped 50 mL Falcon® tube. Samples were shaken at 30 rpm at similar time points (1, 2, 3, 4,
6, 8, and 12 h). Subsequently, 1 mL of sample was collected from the medium and 1 mL of pre-warmed
medium was immediately added to the tubes. Experiments were performed in triplicate (n = 3),
and the collected samples were analyzed with HPLC after necessary dilution with the mobile phase.
The release profile was expressed as cumulative oxaliplatin release calculated using Equation (2).
2.7. In Vivo Oxaliplatin Release in SD Rat’s Intraperitoneal Cavity
In vivo oxaliplatin release from the prepared hydrogels was evaluated in the intraperitoneal
cavity of SD rats, and oxaliplatin solution was also evaluated for comparison. Briefly, a total of fifteen
male SD rats, aged 4–6 weeks, were randomly divided into three groups (n = 5, per group) and were
anesthetized with isoflurane. Intra-abdominal adhesions were induced to mimic the postoperative
surgical conditions, as described previously [23]. The peritoneum was exposed by a 5-cm ventral
midline incision. The left abdominal sidewall was scraped with a 1 cm2 piece of 100-grit sandpaper
200 times. In group 1, oxaliplatin solution was introduced, whereas, group 2 and 3 were exposed to
oxaliplatin powder and oxaliplatin-PLGA microparticles, loaded into HC21 hydrogel, respectively.
All the rats from each group were administered oxaliplatin in the form of a solution or loaded into
hydrogel at a dose level of 5 mg/kg body weight [24]. The abdominal layers and skin incision were then
completely closed, and each rat was kept separately in single cases. All surgeries were performed by the
same individual. At predetermined time interval (0.5, 1, 1.5, 2, 3, 5, 8, 14, 24, and 48 h), approximately
1-mL blood samples were collected from the conjunctiva using a capillary tube and kept in an ice bath.
Blood samples collected from the rat’s conjunctiva were centrifuged at 10,000 rpm (9425× g) for
10 min at 4 ◦C. The supernatant plasma was obtained and stored at −80 ◦C until analyzed. The frozen
plasma samples were thawed, and approximately 200 ± 5 mg was weighed. The samples were
oxidized into metals and organic materials by treating with 6 mL nitric acid using a microwave
sample pre-treatment machine equipped with platinum (Pt) sensor (Microwave Reaction System,
Multi-wave PRO, Anton Paar, Graz, Austria). Samples were heated at predefined temperature and
pressure (200 ± 0.5 ◦C and 4.0 MPa) for 1 h and diluted up to 30 mL with deionized water, and the
concentrations of Pt were analyzed using ICP-MS (NexION 300 D, PerkinElmer, Waltham, MA, USA).
Pharmacokinetic parameters AUC0–48h (area under curve), Cmax (peak concentration), and Tmax (time to
peak concentration) were calculated using noncompartmental analysis.
After the last blood sample collection at 48 h, rats were housed individually in standard case with
a 12-h light-dark cycle. The rats were fed a standard diet, provided with purified water, and were
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allowed to move freely. After 10 days, they were sacrificed, and the peritoneum was opened. For all
rats, adhesion type and extent were assessed, and photographs were taken.
2.8. High-Performance Liquid Chromatography (HPLC) Analysis
In vitro oxaliplatin release and % EE were determined by using HPLC Agilent 1200 Infinity Series
HPLC system (Agilent Technologies, Waldbronn, Germany). Briefly, XTerra™ RPC18 column (particle
size 5 µm, inside diameter 4.6 mm, and length 250 mm; Waters Corporation, Milford, MA, USA) at 210
nm using an HPLC-UV spectrometer (Agilent 1290 infinity). The mobile phase was a 20:80 mixture
of ACN and deionized water and was set to a flow rate of 0.8 mL/min (Model 1260 Quat Pump VL).
The samples were diluted as necessary, and 20 µL of each sample was injected using an autosampler
(Model 1260 ALS).2.9. Statistical Analysis
In vitro percent (%) cumulative oxaliplatin release and in vivo pharmacokinetic study data are
expressed as the means ± standard deviations. The t-test or two-sided RM ANOVA and Bonferroni test
were applied to the analyses of the differences between the groups. A p value < 0.05 was considered as
a statistically significant difference.
3. Results and Discussion
3.1. Characterization of PLGA Microparticles
PLGA-based microparticles were prepared using the double emulsion method. The microparticles
were characterized for size, morphology, and encapsulation efficiency. As shown in Table 1,
oxaliplatin-loaded PLGA microparticles had a particle size of more than 1 µm diameter, with a small
standard deviation. Encapsulation efficiency was 77.9 ± 2.8%, which is excellent for a hydrophilic
drug like oxaliplatin. Although the encapsulation of hydrophilic drugs in PLGA microparticles is
challenging due to the partitioning of weakly associated drugs from the oil phases to the external
water phase, the double emulsion technique is the most commonly used method for encapsulating
hydrophilic drugs. In addition, the SEM image shown in Figure 2A reveals the morphology of the
microparticles. Uniform size and spherical particles were observed, which is in agreement with the
particle size results. To fulfill the aims of this study, PLGA microparticles were further loaded into HC
hydrogels and the in vitro release and in vivo pharmacokinetic studies were conducted.
Table 1. Compositions and characterizations of Poly-(d,l-lactide-co-glycolide) (PLGA) microparticles
and hyaluronic acid (HA) and carboxymethyl cellulose sodium (CMCNa)-based cross-linked
(HC) hydrogels.
Particles Method
Weight Ratio
Particle Size (nm)
(Mean ± SD)
Encapsulation
Efficiency (%)
(Mean ± SD)Oxaliplatin PLGA502 H HA CMCNa
Oxaliplatin-PLGA
Microparticles
Double
Emulsion 1 50 - - 1100.4 ± 257.7 77.9 ± 2.8
HC12 Hydrogel Synthesis by
cross-linking
reaction
- - 1 2 - -
HC21 Hydrogel - - 2 1 - -
3.2. Preparation and Characterization of HC Hydrogels
Cross-linked HC hydrogels were prepared using variable weight ratios of HA and CMCNa.
HC hydrogel synthesis was carried out based on our previous description [18]. In the presence of
ADH (as a nucleophile), EDC (a water-soluble carbodiimide) linked both HA and CMCNa molecules
with its amine group. EDC is not incorporated into the final product, but converts into a non-toxic
water-soluble urea derivative, which is removed by dialysis. Moreover, CH2COO−anions provided
by CMCNa react with H+ ions, leading to carboxyl group formation and facilitation of cross-linking.
Therefore, the reaction in the presence of EDC is pH-dependent and was performed at pH 4.75 ± 0.05.
Pharmaceutics 2019, 11, 392 7 of 13
To evaluate the rheology of the HC hydrogel along with the commercial product Guardix-Sol®,
a Brookfield Digital Rheometer was used. All measurements were performed at 37 ± 0.5 ◦C, with shear
rates ranging from 200 to 500 s−1. All hydrogels followed non-Newtonian shear thinning (pseudo)
plastic flow behavior (Figure 2B). Decreasing viscosity with increasing shear rates was observed, which
demonstrated viscosity-dependent shear rates [25].
In addition, variable ratios of the composition (HA and CMCNa) alter the viscosity of the HC
hydrogels. The order could be written as follows: HC21 > HC12, as markedly increased viscosity was
observed with HA. The highest viscosity was observed with the HC21 formulation, whereas the lowest
viscosity was observed with HC12. The viscosity of Guardix-Sol® was measured for comparison
with those of the synthesized HC hydrogels, and it showed moderate viscosity. The rheology results
correlated with the mechanical characteristics of the polymer, in which viscosity scaled linearly
with molecular weight. The mechanical properties (entanglement phenomenon) of the polymers
increased with increasing molecular weight. Finally, the hydrogels were loaded with oxaliplatin-PLGA
microparticles and their in vitro and in vivo characteristics were evaluated.
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3.3. In Vitro Oxaliplatin Release Study
An in vitro oxaliplatin release study was conducted on oxaliplatin-PLGA microparticles generated
using the double emulsi n method. I addition, ox liplati -PLGA microparticles and oxaliplatin
powder were dispersed into hyd ogels (HC12, HC21, and Guardix-Sol®), and an in vitro oxaliplatin
release study was cond cted. Plots of umulative oxaliplatin rele se (%) versu time (h) are shown in
Figur 3A–C. In vitro release profile f r oxaliplatin-PLGA microparticles (red cl sed circle; () showed
immediate release. With an initial burst release, about 63.2% oxaliplatin was released at 4 h. Oxaliplatin
release from PLGA microparticles is a combination of diffusion and bioerosion mechanism [26]. During
the diffusion stage, oxaliplatin release occurs by diffusion through aqueous channels. The release could
also be triggered by the external pores on the surface or through leaching of the oxaliplatin at or near
the surface, leading to an initial burst release. Besides, the standard deviation values of the results of
the in vitro release study for the hydrogels were low, which indicate excellent reproducibility of the
release behavior. However, when oxaliplatin-PLGA microparticles were loaded into three different
hydrogel systems, HC12, HC21, and Guardix-Sol®, slight initial burst release was observed. Although
the rate of burst release was almost the same for the three systems, HC12, with the lowest viscosity,
showed the maximum release. In contrast, the higher the viscosity of the hydrogel system, the lower
the burst and sustained release observed. This may be due to low leaching of the drugs and high
protection of the microparticles by the hydrogels.
Table 2 demonstrated the kinetic models adopted for evaluation. Where Mt was the cumulative
drug released at time t and M was the initial drug present in the PLGA icroparticles-loaded hydrogels.
k1, kH, and kKP are the first order, Higuchi, and Korsmeyer-Peppas release constant, respectively.
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Mt/M∞ was the fraction of drug released at time t, and n was the diffusional release exponent
symbolic of the release mechanism. The rate of oxaliplatin release from the HC12, Guardix-Sol®
and HC21-loaded PLGA microparticles were slower and constant compared with the oxaliplatin
powder-loaded hydrogels, as indicated by the KH values of 18.9686, 17.5626, and 20.6559% h1/2,
respectively. Release constants were determined using the slope of the appropriate plots, and the
regression coefficient (R2) was obtained through linear regression analysis (Table 2). The coefficient
of determination (R2) was used as an indicator of curve fit for each of the considered models [27].
The regression coefficients R2, from the Korsmeyer-Peppas plots were 0.9342, 0.9554, and 0.9366 for
HC12, Guardix-Sol® and HC21, respectively, thus the log of cumulative drug release was proportional
to the log of time. The best linear fits were observed for the PLGA microparticles-loaded hydrogels
using both the Higuchi and Korsmeyer-Peppas models, suggesting that oxaliplatin release from the
PLGA microparticles-loaded hydrogels were diffusive process. Oxaliplatin gradually dissolved into
the fluid within the swelled hydrogels, then slowly diffused from polymeric networks of the hydrogels.
Table 2. Release rate constants and regression coefficient R2 obtained from drug release profile based
on kinetic equations.
Equations
Loaded in HC12 Hydrogel Loaded in Guardix-Sol
®
Hydrogel
Loaded in HC21 Hydrogel PLGAMicroparticle
Oxaliplatin
Powder
PLGA
Microparticle
Oxaliplatin
Powder
PLGA
Microparticle
Oxaliplatin
Powder
PLGA
Microparticle
a Higuchi model: kH
(% h1/2) 28.5970 18.9686 22.1635 17.5626 24.3401 20.6559 20.0882
R2 0.6738 0.9611 0.7431 0.9783 0.7746 0.9485 0.8026
b First—Order model:
k1 (h−1)
0.0302 0.0421 0.0263 0.0469 0.0379 0.0522 0.0219
R2 0.1639 0.6646 0.2327 0.7224 0.2640 0.6451 0.4145
c Korsmeyer—Peppas
model: kKP
0.4517 0.5033 0.3750 0.5475 0.5352 0.6308 0.2884
R2 0.5495 0.9342 0.6099 0.9554 0.6512 0.9366 0.7767
a Higuchi model: (Mt = kH × t1/2); b First—Order model: (ln Mt = lnM + k1 × t); c Korsmeyer—Peppas model:
(Mt/M∞ = kKP × tn).
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Although hydrogels are swellable materials with high water content, which readily allow the
release or leaching of hydrophilic drugs through the channels, high viscosity might hinder this process.
Therefore, release may be completed through bioerosion. In this study, three different hydrogel
systems—HC12, HC21, and Guardix-Sol®, were loaded with oxaliplatin powder and oxaliplatin-PLGA
microparticles. The HC12 hydrogel system (low viscosity) was loaded with oxaliplatin powder and
more than 90% oxaliplatin release occurred within 3 h, followed by saturated release behavior up to
12 h. However, oxaliplatin-PLGA microparticles loaded into the HC12 hydrogel showed a slower
release pattern than that of the oxaliplatin powder. Approximately 50% oxaliplatin was released after
4 h, followed by 64.2% release up to the end of the experiment (p < 0.05). Due to the less hydrophilicity
of the PLGA copolymers, they absorb less water, and subsequently degrade more slowly. Therefore,
drug release from the PLGA microparticles was delayed. In the case of Guardix-Sol®, with moderate
viscosity, a sustained release profile was observed for the oxaliplatin-PLGA microparticles. During the
first 2 h of the release study, less than 30% of oxaliplatin was released; however, 59.25% of oxaliplatin
was released after the same amount of time when loaded with oxaliplatin powder (p < 0.05).
In addition, the HC21 hydrogel system (high viscosity) showed a similar sustained release profile
when loaded with oxaliplatin-PLGA microparticles. In all three systems, more rapid oxaliplatin
release was observed when oxaliplatin was loaded as a powder compared to that when loaded
as microparticles. The release rate was faster than those of both oxaliplatin-PLGA microparticles
and oxaliplatin-PLGA microparticles-loaded hydrogels. Additionally, both Guardix-Sol® and HC21
showed similar sustained release patterns up to 12 h. Although PLGA microparticles were generated
using the well-known double emulsion method, further studies are necessary to establish process
parameters and extensive characterization of the particles.
3.4. Pharmacokinetics in Rats
The bioavailability of oxaliplatin-PLGA microparticles loaded into the HC21 hydrogel was
evaluated in rats. Figure 4 shows the mean concentration–time profiles of oxaliplatin in rats after
a single dose (5 mg/kg) of oxaliplatin solution, oxaliplatin-PLGA microparticles, and oxaliplatin
powder loaded into the HC21 hydrogel. The samples were introduced through a midline incision to
open the peritoneum immediately after introducing intra-abdominal adhesions by multiple scraping
to mimic postoperative surgical conditions. Intraperitoneal absorption of oxaliplatin solution was
obviously higher than that of the hydrogel loaded samples (oxaliplatin-PLGA microparticles and
oxaliplatin powder). For oxaliplatin solution AUC0–48h, Cmax, and Tmax were 8181.51 ± 176.89 ng·h/mL,
2265.28 ± 192.51 ng/mL, and 1.0 h, respectively. In the case of oxaliplatin powder loaded into the
HC21 hydrogel, AUC0–48h, Cmax, and Tmax were 16,571.37 ± 139.13 ng·h/mL, 690.63 ± 140.54 ng/mL,
and 1.5 h, respectively. Intraperitoneal bioavailability of oxaliplatin was significantly increased
by up to 2-fold in the HC21 hydrogel (Table 3). In particular, 1.9-fold higher bioavailability was
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observed in the case of oxaliplatin-PLGA microparticles loaded into the HC21 hydrogel compared
to that of the oxaliplatin solution. AUC0–48h, Cmax, and Tmax were 16,012.12 ± 188.75 ng·h/mL,
528.75 ± 144.50 ng/mL, and 1.5 h, respectively. Moreover, mean residence time (MRT) was increased
by 2.7-fold for oxaliplatin-PLGA microparticles when loaded into the HC21 hydrogels (p < 0.05).
When the oxaliplatin-PLGA microparticles were loaded into the HC21 hydrogel, oxaliplatin release
rate decreased due to the multi-layered encapsulation, which was observed from the in vitro release
study. Therefore, in the high, moderate, and low viscous hydrogels (HC21, Guardix-Sol®, and HC12,
respectively), oxaliplatin release from the PLGA microparticles, followed by release from the hydrogels,
was observed in a sustained manner (Figure 3). Furthermore, using sustained-release hydrogels allows
a longer residence time of the component at the application site (intraperitoneal after cytoreductive
surgery), which offers additional benefits through the prevention of intra-abdominal adhesion and
improvement in the delivery of intraperitoneal oxaliplatin from the PLGA microparticles.
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Figure 4. Plasma concentration-time profile of Pt in rats after intra-peritoneal administration of
oxaliplatin powder and oxaliplatin-PLGA microparticles-loaded in HC21 hydrogel, and oxaliplatin
solution. Data are expressed as the Mean ± standard deviation (n = 5). *, p < 0.05 represents a significant
difference, two-sided RM ANOVA and Bonferroni test.
Table 3. In vivo pharmacokinetic parameters after intra-peritoneal administration to rats (n = 5).
Formulations
Pharmacokinetic Parameters
Cmax (ng/mL) Tmax (h) AUC0–48h (ng·h/mL) MRT (h)
Oxaliplatin solution 2265.28 ± 192.51 1 8181.51 ± 176.89 4.36 ± 0.65
Oxaliplatin powder loaded HC21 690.63 ± 140.54 1.5 16571.37 ± 139.13 10.29 ± 0.33
Oxaliplatin-PLGA microparticle loaded HC21 528.75 ± 144.50 1.5 16012.12 ± 188.75 12.02 ± 0.41
3.5. Intraperitoneal Anti-Adhesion Effect
An extensive investigation of the intraperitoneal anti-adhesion efficacy of C hydrogels as
conducted in our previous study, after introducing peritoneal injury to generate peritoneal adhesion [18].
HC hydrogel groups (treated) showed the highest anti-adhesion barrier compared to the control group
(non-treated). In the present study, the pharmacokinetic para eters of the PLGA microparticles loaded
into the HC21 hydrogel were evaluated and compared with those of oxaliplatin powder loaded into
hydrogels. Artificial injury on the left abdominal sidewall was introduced to mimic surgical conditions
and observe the anti-adhesion barrier effect of hydrogel samples followed by the intraperitoneal
delivery of oxaliplatin. The method was adopted from experienced surgeons certainly feasible in
human administration after cytoreductive surgery in colorectal cancer treatment. Intraperitoneal
anti-adhesion effect was observed and recorded photographically. Figure 5 shows a photographical
representation of adhesion characteristics of the study groups.
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Figure 5. Photographical expression of in vivo anti-adhesion efficacy observed in rats after introducing
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oxaliplatin-PLGA microparticles-loaded HC21 hydrogel.
HC21 hydrogel samples exhibited an efficient anti-adhesion barrier effect towards the injury.
Although hydrogels were not intended to cure the injury, long resident time hydrogels significantly
prevented adhesion along with rapid recovery of the injury, possibly due to mechanical separation
from the injury site [28]. As reported previously, the washing away or displacement of the oxaliplatin
solution from the application site allows less barrier or protection to the injury site [29]. Therefore,
dense adhesion on the abdominal wall was observed, and, although current study was not intended to be
carried out extensively, adhesion scoring and extent (as disclosed in a previous report) and photographic
representation demonstrated the superiority of the hydrogels in terms of the anti-adhesion barrier. In the
hydrogel-loaded samples, no or minor adhesion was observed in the treated rat abdomen (Figure 5B,C).
Although two different samples were evaluated after loaded in HC21 hydrogel both oxaliplatin
powder and oxaliplatin-PLGA microparticles loaded hydrogels showed significant improvement as
anti-adhesion barrier. Subsequently, both hydrogel systems showed rapid wound recovery effect may
be due to mechanical separation- could be seen from the blood spot in Figure 5C. Instead, oxaliplatin
solution presents no barrier to the injure site and dense abdominal adhesion was observed. The HC21
hydrogel-loaded sample showed enhanced anti-adhesion protection to the injury site, suggesting
its potential therapeutic application in CRC patients who have undergone cytoreductive surgery.
Although the current study evaluated the pharmacokinetic profile of PLGA microparticle-loaded HC
hydrogels, a further pharmacodynamics study on a CRC model is required to evaluate the composition
of the hydrogels.
4. Conclusions
Oxaliplatin-PLGA microparticles were loaded into hydrogels to improve intraperitoneal
chemotherapy with an anti-adhesion barrier effect. In an in vitro release study, we observed sustained
oxaliplatin release from PLGA microparticles loaded into hydrogels in comparison with the unloaded
sample. Moreover, in the in vivo pharmacokinetics study on rats, PLGA microparticle-loaded hydrogels
showed higher bioavailability compared to oxaliplatin solution. Furthermore, visual observations
revealed that the HC hydrogels were effective as an intra-abdominal anti-adhesion barrier.
Therefore, intraperitoneal delivery of PLGA microparticle-loaded hydrogels, which have an effective
intra-abdominal anti-adhesion barrier, is expected to provide an optimized alternative therapy for
CRC. Earlier reports of cytotoxicity study for PLGA (RG502H) microparticles exhibited non-cytotoxic
at increasing concentration [30]. Additionally, both HA and CMCNa are considered as inert and
non-cytotoxic. However, cytotoxicity profile for the novel oxaliplatin-PLGA microparticles-loaded HC
hydrogels were yet to revealed. As the investigation undertaken in current study was preliminary,
pharmacokinetic and anti-adhesion efficacy of this multi-complex drug delivery system, further studies
Pharmaceutics 2019, 11, 392 12 of 13
are required to address cytotoxicity, cell viability, toxicity in liver function, and efficacy in CRC model
in vivo.
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